Full Archive

Occupational and Environmental Exposure to Asbestos Reduces Longevity in Patients

Mesothelioma is a hard cancer to treat that is mainly caused by asbestos. People with this cancer typically do not live very long after diagnosis, but some people live longer than expected. A study recently published in the journal Toxics looked at people with mesothelioma and asbestos-caused lung cancer. All[…]

Read More »

Altered CAR-T Cell Therapy for the Treatment of Mesothelioma

Immunotherapy is an innovative and groundbreaking way to treat cancer. It uses the immune system to fight and kill cancer cells. One immunotherapy treatment that is showing good results for certain cancers is called CAR-T cell therapy, which is able to target specific proteins on cancer cells. One of the[…]

Read More »

Radiation and Immunotherapy Combination Improves Survival in Lung Cancer Patients

A new study looking at low dose radiation and immunotherapy is showing promising results for non-small cell lung cancer. Patients treated with the combination had higher progression free survival compared to patients who received immunotherapy alone. Research was completed at Weill Cornell Medicine, NewYork-Presbyterian as well as at Columbia University[…]

Read More »

GPC3/​Mesothelin-CAR-γδT Cells Against Cancers

Primary Outcome Measures Number of Patients with Dose Limiting Toxicity A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the γδT cells, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5. Secondary Outcome Measures Percent of Patients with best[…]

Read More »

ADI-PEG 20 is Being Tested on Non-Epithelioid Mesothelioma

Polaris Group recently announced an application for a rolling submission of a new mesothelioma treatment. The Biologic License Application is the first step in becoming approved by the Food and Drug Administration. The treatment, known as ADI-PEG 20, is for the use on non-epithelioid mesothelioma patients alongside pemetrexed and platinum[…]

Read More »

Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA)

Primary Outcome Measures Primary endpoint – To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR) Pathological complete response defined as 0% residual viable tumor cells in the primary tumor and in sampled lymph nodes, following neoadjuvant treatment as assessed by central pathology assessment.[…]

Read More »

Pembrolizumab and Chemotherapy Improve Survival in Patients

Pleural mesothelioma, a cancer mainly caused by asbestos, is a hard cancer to treat. Diagnosis usually occurs when it is in a late stage, leading to limited treatment options. New clinical trials are always being performed to try to find a new treatment approach that could possibly extend the lives[…]

Read More »

CIRT Radiation Therapy Beneficial for Lung Cancer Patients

Surgery is usually the first choice for patients and doctors for the treatment of early-stage cancer. There are other options though like radiotherapy. A special type of radiotherapy called Carbon-ion radiotherapy (CIRT)has become popular with doctors.  A study in Japan showing how the therapy can benefit patients with early-stage lung[…]

Read More »

Checkmate743 Showed Higher Toxicity in a Real World Setting

A group of Australian patients receiving Checkmate743 therapy saw higher levels of toxicity compared to CheckMate743 clinical trial patients. Checkmate743 consists of a dual treatment of ipilimumab and nivolumab and is the standard of care for patients with unresectable pleural mesothelioma. Unresectable means patients are not able to receive surgery[…]

Read More »